Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea.
Genzyme Corp is developing tolevamer, an anionic toxin-binding polymer that binds and neutralizes the Clostridium difficile A and B toxins, for the potential treatment of C difficile-associated diarrhea (CDAD). Two phase III clinical trials of tolevamer in patients with CDAD have been completed and results from the second trial are expected to be released imminently.
Scheinfeld
Noah
N
Columbia University School of Medicine, St Luke's-Roosevelt Hospital Center, 10th Ave and 59th St, New York, NY 10025, USA. Scheinfeld@earthlink.net
Biggers
Kristen
K
D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D016360:Clostridioides difficile / Q000187:drug effects; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D010330:Patents as Topic; D011108:Polymers / Q000008:administration & dosage* / Q000493:pharmacokinetics; D013451:Sulfonic Acids
D000900:Anti-Bacterial Agents; D011108:Polymers; D013451:Sulfonic Acids; C077114:styrenesulfonic acid polymer